Medifast announced its financial results for the fourth quarter and full year 2025. Revenue during the fourth quarter reached $75.1 million while full-year 2025 revenue totaled $385.8 million. Coach productivity turned positive year-over-year for the first time since 2022, which the company stated has historically been a lead indicator of broader improvement. There was also a significant increase in coach-led meetings, which reflects a more energized coach base.
“As we enter 2026, Medifast is moving from defining its business transformation strategy to executing on a new path to growth, leading to profitability as we become wholly focused on optimal metabolic health,” said Dan Chard, Medifast Chairman and Chief Executive Officer. “Our foundational work of the past two years has established a direction for future growth, and with these plans in place, we are reinstating annual guidance as we execute against the path we are on to become a metabolic health company.”
Fourth quarter revenue experienced a 36.9% decline, which was primarily driven by a decrease in the number of active earning coaches. The total number of active earning coaches decreased 40.6% year-over-year, driven by continued pressure with client acquisition and rapid adoption of GLP-1 medications for weight loss. Gross profit during the quarter fell 40.9% to $52.1 million. Net loss during the quarter was $18.1 million, or $1.65 loss per diluted share.
Full-year 2025 revenue fell 36% with a net loss of $18.7 million, or $1.70 loss per diluted share. The company ended the year with cash, cash equivalents and investment securities of $167.3 million with no interest-bearing debt. The company now expects first quarter 2026 revenue in the range of $65 million to $80 million.
The post Medifast Reports Q4 and Full Year 2025 Financial Results first appeared on Direct Selling News.
